WHO recommends HPV DNA detection as the primary screening for cervical cancer
Cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020. More than 95% of cervical cancer is due to the human papillomavirus (HPV) persistent infection. To accelerate the elimination of cervical cancer, WHO determines to screen 70% of eligible women at least twice in their lifetime using HPV DNA detection as the primary screening test rather than VIA or cytology.
(Source: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer)
GENEDIAN’s HPV Test Kit
GENEDIAN’s HPV test kit is intended for in-vitro qualitative detection of nucleic acid DNA of up to 16 HPV genotypes in single analysis. The test utilizes amplification of target DNA by the Polymerase Chain Reaction (PCR), with β-globin internal cellular control helps to avoid false negative.
Features and Performances
1. Cost-saving and fast fo…